Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab + Benmelstobart + RT in High-Risk HNSCC Ineligible for Cisplatin
NCT07445048Phase 3Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of benmelstobart in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Disease-Free Survival at 3 years. Started Mar 2026; status: recruiting.
02
Drugs
benmelstobart
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07445048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07445048.